295 related articles for article (PubMed ID: 26779889)
1. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis.
Boyle P; Koechlin A; Bota M; d'Onofrio A; Zaridze DG; Perrin P; Fitzpatrick J; Burnett AL; Boniol M
BJU Int; 2016 Nov; 118(5):731-741. PubMed ID: 26779889
[TBL] [Abstract][Full Text] [Related]
2. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
4. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
[TBL] [Abstract][Full Text] [Related]
5. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
Rhoden EL; Morgentaler A
J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
[TBL] [Abstract][Full Text] [Related]
6. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Zhang Y
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):132-43. PubMed ID: 24445948
[TBL] [Abstract][Full Text] [Related]
7. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
8. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy.
Shoskes DA; Barazani Y; Fareed K; Sabanegh E
Int Braz J Urol; 2015; 41(6):1167-71. PubMed ID: 26742976
[TBL] [Abstract][Full Text] [Related]
10. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis.
Kohn TP; Mata DA; Ramasamy R; Lipshultz LI
Eur Urol; 2016 Jun; 69(6):1083-90. PubMed ID: 26874809
[TBL] [Abstract][Full Text] [Related]
11. Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism.
Gray H; Seltzer J; Talbert RL
Am J Health Syst Pharm; 2015 Apr; 72(7):536-41. PubMed ID: 25788507
[TBL] [Abstract][Full Text] [Related]
12. The effect of testosterone replacement therapy on prostate-specific antigen (PSA) levels in men being treated for hypogonadism: a systematic review and meta-analysis.
Kang DY; Li HJ
Medicine (Baltimore); 2015 Jan; 94(3):e410. PubMed ID: 25621688
[TBL] [Abstract][Full Text] [Related]
13. Is testosterone treatment good for the prostate? Study of safety during long-term treatment.
Feneley MR; Carruthers M
J Sex Med; 2012 Aug; 9(8):2138-49. PubMed ID: 22672563
[TBL] [Abstract][Full Text] [Related]
14. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.
Bhasin S; Travison TG; Pencina KM; O'Leary M; Cunningham GR; Lincoff AM; Nissen SE; Lucia MS; Preston MA; Khera M; Khan N; Snabes MC; Li X; Tangen CM; Buhr KA; Thompson IM
JAMA Netw Open; 2023 Dec; 6(12):e2348692. PubMed ID: 38150256
[TBL] [Abstract][Full Text] [Related]
15. Association between prostate-specific antigen and serum testosterone: A systematic review and meta-analysis.
Kim DK; Noh JW; Chang Y; Lee HY; Park JJ; Ryu S; Kim JH
Andrology; 2020 Sep; 8(5):1194-1213. PubMed ID: 32329181
[TBL] [Abstract][Full Text] [Related]
16. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
18. The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy.
Klap J; Schmid M; Loughlin KR
J Urol; 2015 Feb; 193(2):403-13. PubMed ID: 25260832
[TBL] [Abstract][Full Text] [Related]
19. Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men With Late-Onset Hypogonadism.
Santella C; Renoux C; Yin H; Yu OHY; Azoulay L
Am J Epidemiol; 2019 Sep; 188(9):1666-1673. PubMed ID: 31145457
[TBL] [Abstract][Full Text] [Related]
20. The effect of 5α-reductase inhibitors on prostate growth in men receiving testosterone replacement therapy: a systematic review and meta-analysis.
Cui Y; Zong H; Yang C; Yan H; Zhang Y
Int Urol Nephrol; 2013 Aug; 45(4):979-87. PubMed ID: 23728850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]